FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986390016> ?p ?o ?g. }

• W2986390016 endingPage "viii35" @default.
• W2986390016 startingPage "viii31" @default.
• W2986390016 abstract "BackgroundThe ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib.Patient and methodsA male infant born with a large congenital IFS of the tongue had the tumour surgically resected at age 4 days. Within 2 months, he developed extensive lymph node recurrence that progressed during two cycles of vincristine-doxorubicin-cyclophosphamide chemotherapy. At screening, a large right cervical mass was clinically visible. Magnetic resonance imaging (MRI) revealed bilateral cervical and axillary lymph node involvement as well as infiltration of the floor of the mouth. The largest lesion measured 5.5×4.5×4.4 cm (ca. 55 cm3). The patient started outpatient oral larotrectinib at 20 mg/kg twice daily at age 3.5 months.ResultsAfter 4 days on treatment, the parents noted that the index tumour was visibly smaller and softer. The rapid tumour regression continued over the following weeks. On day 56 of treatment, the first scheduled control MRI showed the target lesion had shrunk to 1.2×1.2×0.8 cm (ca. 0.6 cm3), corresponding to a complete response according to the Response Evaluation Criteria In Solid Tumors version 1.1. This response was maintained over subsequent follow-up visits, and on day 112 at the second control MRI the target lymph node was completely normal. At last follow-up, the disease remained in complete remission after 16 months on larotrectinib, with negligible toxicity and no safety concerns.Conclusion(s)Selective TRK inhibition by larotrectinib offers a novel, highly specific and highly effective therapeutic option for IFS carrying the characteristic ETV6-NTRK3 gene fusion. Its use should be considered when surgery is not feasible. (NCT02637687)" @default.
• W2986390016 created "2019-11-22" @default.
• W2986390016 creator A5002688480 @default.
• W2986390016 creator A5010557443 @default.
• W2986390016 creator A5011059803 @default.
• W2986390016 creator A5014225383 @default.
• W2986390016 creator A5016647861 @default.
• W2986390016 creator A5016737261 @default.
• W2986390016 creator A5025613346 @default.
• W2986390016 creator A5027746254 @default.
• W2986390016 creator A5030504947 @default.
• W2986390016 creator A5032304577 @default.
• W2986390016 creator A5032491051 @default.
• W2986390016 creator A5037060553 @default.
• W2986390016 creator A5060570243 @default.
• W2986390016 creator A5062346231 @default.
• W2986390016 creator A5069314984 @default.
• W2986390016 creator A5086839145 @default.
• W2986390016 creator A5088020064 @default.
• W2986390016 creator A5091832008 @default.
• W2986390016 date "2019-11-01" @default.
• W2986390016 modified "2023-10-16" @default.
• W2986390016 title "Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion" @default.
• W2986390016 cites W1976059757 @default.
• W2986390016 cites W1989543541 @default.
• W2986390016 cites W2019607817 @default.
• W2986390016 cites W2026218170 @default.
• W2986390016 cites W2164547129 @default.
• W2986390016 cites W2252283934 @default.
• W2986390016 cites W2342373567 @default.
• W2986390016 cites W2572335661 @default.
• W2986390016 cites W2740079646 @default.
• W2986390016 cites W2771760183 @default.
• W2986390016 cites W2790254562 @default.
• W2986390016 cites W2795040138 @default.
• W2986390016 cites W2806697314 @default.
• W2986390016 cites W2891457886 @default.
• W2986390016 cites W2891473286 @default.
• W2986390016 cites W2900674461 @default.
• W2986390016 cites W2911070445 @default.
• W2986390016 cites W2912589071 @default.
• W2986390016 cites W4240368944 @default.
• W2986390016 doi "https://doi.org/10.1093/annonc/mdz382" @default.
• W2986390016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6859811" @default.
• W2986390016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32223937" @default.
• W2986390016 hasPublicationYear "2019" @default.
• W2986390016 type Work @default.
• W2986390016 sameAs 2986390016 @default.
• W2986390016 citedByCount "23" @default.
• W2986390016 countsByYear W29863900162019 @default.
• W2986390016 countsByYear W29863900162020 @default.
• W2986390016 countsByYear W29863900162021 @default.
• W2986390016 countsByYear W29863900162022 @default.
• W2986390016 countsByYear W29863900162023 @default.
• W2986390016 crossrefType "journal-article" @default.
• W2986390016 hasAuthorship W2986390016A5002688480 @default.
• W2986390016 hasAuthorship W2986390016A5010557443 @default.
• W2986390016 hasAuthorship W2986390016A5011059803 @default.
• W2986390016 hasAuthorship W2986390016A5014225383 @default.
• W2986390016 hasAuthorship W2986390016A5016647861 @default.
• W2986390016 hasAuthorship W2986390016A5016737261 @default.
• W2986390016 hasAuthorship W2986390016A5025613346 @default.
• W2986390016 hasAuthorship W2986390016A5027746254 @default.
• W2986390016 hasAuthorship W2986390016A5030504947 @default.
• W2986390016 hasAuthorship W2986390016A5032304577 @default.
• W2986390016 hasAuthorship W2986390016A5032491051 @default.
• W2986390016 hasAuthorship W2986390016A5037060553 @default.
• W2986390016 hasAuthorship W2986390016A5060570243 @default.
• W2986390016 hasAuthorship W2986390016A5062346231 @default.
• W2986390016 hasAuthorship W2986390016A5069314984 @default.
• W2986390016 hasAuthorship W2986390016A5086839145 @default.
• W2986390016 hasAuthorship W2986390016A5088020064 @default.
• W2986390016 hasAuthorship W2986390016A5091832008 @default.
• W2986390016 hasBestOaLocation W29863900161 @default.
• W2986390016 hasConcept C121332964 @default.
• W2986390016 hasConcept C126322002 @default.
• W2986390016 hasConcept C126838900 @default.
• W2986390016 hasConcept C141071460 @default.
• W2986390016 hasConcept C142424586 @default.
• W2986390016 hasConcept C142724271 @default.
• W2986390016 hasConcept C143409427 @default.
• W2986390016 hasConcept C143998085 @default.
• W2986390016 hasConcept C2776495794 @default.
• W2986390016 hasConcept C2776694085 @default.
• W2986390016 hasConcept C2776755627 @default.
• W2986390016 hasConcept C2779429289 @default.
• W2986390016 hasConcept C2780849966 @default.
• W2986390016 hasConcept C71924100 @default.
• W2986390016 hasConcept C87355193 @default.
• W2986390016 hasConceptScore W2986390016C121332964 @default.
• W2986390016 hasConceptScore W2986390016C126322002 @default.
• W2986390016 hasConceptScore W2986390016C126838900 @default.
• W2986390016 hasConceptScore W2986390016C141071460 @default.
• W2986390016 hasConceptScore W2986390016C142424586 @default.
• W2986390016 hasConceptScore W2986390016C142724271 @default.
• W2986390016 hasConceptScore W2986390016C143409427 @default.
• W2986390016 hasConceptScore W2986390016C143998085 @default.
• W2986390016 hasConceptScore W2986390016C2776495794 @default.

• next